Medtronic PLC $MDT Position Trimmed by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH cut its stake in Medtronic PLC (NYSE:MDT) by 3.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,569,975 shares of the medical technology company’s stock after selling 51,468 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.12% of Medtronic worth $149,524,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Delos Wealth Advisors LLC acquired a new stake in shares of Medtronic in the second quarter valued at about $27,000. Corundum Trust Company INC bought a new stake in shares of Medtronic during the third quarter valued at approximately $27,000. Steigerwald Gordon & Koch Inc. bought a new position in shares of Medtronic in the third quarter valued at approximately $33,000. Tripletail Wealth Management LLC bought a new position in Medtronic in the 3rd quarter worth approximately $34,000. Finally, GFG Capital LLC bought a new position in shares of Medtronic in the 2nd quarter worth $36,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Trading Up 1.9%

MDT opened at $98.64 on Wednesday. The company’s 50 day simple moving average is $99.14 and its two-hundred day simple moving average is $95.06. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The firm has a market capitalization of $126.46 billion, a price-to-earnings ratio of 26.59, a price-to-earnings-growth ratio of 2.55 and a beta of 0.71. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. Medtronic’s revenue was up 6.6% compared to the same quarter last year. During the same period last year, the business earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on MDT shares. Daiwa Capital Markets boosted their price target on Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. Cowen restated a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Jefferies Financial Group reaffirmed a “hold” rating and set a $110.00 target price on shares of Medtronic in a research report on Wednesday, November 19th. UBS Group increased their price target on shares of Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a research report on Wednesday, November 19th. Finally, Stifel Nicolaus raised their price target on shares of Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a report on Thursday, October 9th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus target price of $110.28.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).